Solventum (SOLV)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$91.69-0.81%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · SOLV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 5.7% |
| Our one-year growth estimate | diamond | 1.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 3.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 25 industry peers · Company calendar date is not available
SOLV — litigation filed
Dated 2026-06-05
Other Events. On May 10, 2024, Plaintiff Eric Gilbert (the “Plaintiff”), on behalf of a putative class of stockholders of Solventum Corporation (the “Company”), filed a Verified Class Action Complaint (the “Action”) in the Court of Chancery of the State of Delaware (the “Delaware Court”), challenging the validity of certain aspects of the advance notice and stockholder nomination provisions of the By-laws of the Company. On September 20, 2024, the Company modified the challenged provisions by…
Why it matters: Free cash flow shows how much cash Solventum generates after expenses. It is important for future investments.
Supportive ifFree cash flow for Q2 2026 is around $50 million or more.
Worry ifFree cash flow for Q2 2026 is negative or below $50 million.
Why it matters: The outcome could impact Solventum's reputation and financials. A ruling in favor of the plaintiff could lead to further legal costs.
Worry ifCourt rules in favor of Solventum, dismissing the class action lawsuit.
Less concerning ifA court ruled against Solventum. This may lead to financial problems.
Why it matters: This separation is key for Solventum to become a focused MedTech company. It may help shareholders.
Supportive ifThe separation is done within the planned 12 to 18 months.
Worry ifThe separation is delayed past the 18-month target or is not completed.
Why it matters: How the lawsuit ends may affect how investors feel and their confidence.
Watch forCourt ruling dismisses the lawsuit with no further claims.
Also watch forThe court ruled for the plaintiff. This may lead to possible liabilities.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$130 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $255 loss on $10,000 · 2.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,746 loss on $10,000 · 27.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The lawsuit's outcome could change governance and affect investor trust.
Worry ifThe court decided for Solventum. It confirmed the rules for governance.
Less concerning ifThe court ruled against Solventum. This will change the governance rules.
Why it matters: Updates will show if Solventum is making progress on its cost-saving goals.
Watch forManagement says they made good progress in saving costs from the plan.
Also watch forManagement reports delays in the plan's rollout.
Why it matters: The separation could sharpen Solventum's focus on MedTech. This may unlock shareholder value and drive growth.
Supportive ifManagement will share a clear timeline for the split in the next quarter.
Worry ifNo updates or delays in the split beyond the expected 12 to 18 months.
Why it matters: Keeping this guidance shows strong earnings and confidence from management.
Supportive ifManagement reaffirms adjusted EPS guidance in the next earnings call.
Worry ifManagement cuts adjusted EPS guidance to below $6.40 for the next earnings call.
Why it matters: Free cash flow is crucial for funding growth initiatives. Negative cash flow could signal ongoing challenges.
Worry ifFree cash flow turns positive in Q3. This shows better cash generation.
Less concerning ifFree cash flow remains negative. This suggests ongoing financial problems.
Why it matters: Management has set a target of 2.0% to 3.0% organic sales growth for 2026. Changes could signal shifts in market conditions or execution.
Watch forManagement raises the sales growth estimate to over 3.0% in the next report.
Also watch forThe estimate falls below 2.0%. This shows possible problems with sales.
Why it matters: This growth would show strong performance. It matches management's new guidance for 2026.
Supportive ifOrganic sales growth reported at 2.5% or more in the next quarterly earnings report.
Worry ifOrganic sales growth below 2.0% in the next earnings report.
Why it matters: Better free cash flow shows improved capital management and helps growth.
Supportive ifFree cash flow reported at $200 million or more in the next quarterly earnings report.
Worry ifFree cash flow remains negative or below $200 million in the next quarterly earnings report.